Finoriq research workspace
ASSEMBLY BIOSCIENCES, INC. (ASMB) SEC Filings & Filing Highlights
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the. Review ASMB SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
- Company
- ASSEMBLY BIOSCIENCES, INC. (ASMB)
- Ticker
- ASMB
- Market Cap
- $402.7M
- Latest Price
- $25.34
- Industry
- Biotech & Pharma
ASSEMBLY BIOSCIENCES, INC. (ASMB) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ASSEMBLY BIOSCIENCES, INC. (ASMB).
| Event | Form | Date |
|---|---|---|
| Director NomineeOn June 4, 2026, the matters listed below were submitted to a vote of the Company's stockholders at the Annual Meeting through the solicita... | 8-K5.07 | 2026-06-05 |
| Amendment No. 3 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences,...Amendment No. 3 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. (the "Company") Annual Meeting of Stock... | 8-K5.02 | 2026-06-05 |
| Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Live...Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases | 8-K8.01 | 2026-05-22 |
| Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Live...Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases | 8-K7.01 | 2026-05-22 |
| Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded...Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants | 8-K8.01 | 2026-05-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.